SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%
News
ITCI
--
0.00%
--
Did Hedge Funds Make The Right Call On Intra-Cellular Therapies Inc (ITCI)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 1d ago
Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will h
GlobeNewswire · 2d ago
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
Zacks · 07/07 13:52
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
GlobeNewswire · 06/29 13:00
Intra-Cellular's ITI-214 shows positive action in heart failure study
Seeking Alpha - Article · 06/29 12:45
Intra-Cellular Therapies Announces Top-line Results From ITI-214 Phase I/II Study In Patients With Heart Failure
Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart
Benzinga · 06/29 12:18
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/25 15:13
Do Hedge Funds Love Intra-Cellular Therapies Inc (ITCI)?
In this article you are going to find out whether hedge funds think Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there h
Insider Monkey · 06/24 01:08
Intra-Cellular (ITCI) Moves to Buy: Rationale Behind the Upgrade
Zacks · 06/23 17:00
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com · 06/17 21:04
3 Strong Buy Pharmaceutical Stocks With Major Catalysts Approaching
TipRanks · 06/17 14:43
How Intra-Cellular Therapies (ITCI) Stock Stands Out in a Strong Industry
Zacks · 06/11 14:00
Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options
Zacks · 06/04 13:49
Intra-Cellular Therapies' Shares March Higher, Can It Continue?
Zacks · 05/26 16:05
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 14, 2020 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central.
GlobeNewswire · 05/14 12:00
Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 05/13 21:15
Intra-Cellular Therapies, Inc. (ITCI) CEO Dr. Sharon Mates on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 20:02
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St. · 05/09 14:52